两步法联合脂肪变生物标志物与多参数定量超声提升肝脂肪变无创诊断
这项前瞻性多中心横断面研究纳入234例疑似MASLD患者,构建基于衰减系数(AC)、肝脏纹理指数(LTI)等定量超声参数的模型,并提出先检测脂肪变生物标志物(VAI或TyG指数)再行超声模型评估的两步法,使诊断准确率从0.85提升至0.88。
要点
- AC与LTI联合模型诊断脂肪变AUC达0.94,加入空腹血糖未显著提升。
- 先测VAI或TyG指数再行超声模型的两步法可提高诊断准确率。
- 多参数定量超声有望成为MRI PDFF之外的无创脂肪变评估手段。
局限性
- 横断面设计无法评估两步法的纵向诊断价值。
- 样本来自中国五家三级医院,外推性需验证。
- 脂肪变患病率高达73.93%,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop optimized models integrating multiple quantitative US parameters and steatosis biomarkers for discriminating steatosis in patients with suspected metabolic dysfunction-associated steatotic liver disease (MASLD).
METHODS: This prospective cross-sectional multicenter study consecutively enrolled participants with suspected MASLD from five tertiary hospitals in China (July 2023-April 2024). All participants underwent multiparametric US (attenuation coefficient [AC], liver texture index [LTI], and hepatorenal index [HRI]) and MRI proton density fat fraction (PDFF). Steatosis discrimination models were constructed using US parameters alone or combined with clinical indicators. A two-step approach involving steatosis biomarkers followed by a US model was proposed. Area under the receiver operating characteristic curve (AUC) analysis was used to evaluate the diagnostic performance.
RESULTS: Among the 234 participants (mean age, 38.12 ± 9.56 y; 110 male), 173 (73.93%) had steatosis. AC (odds ratio [OR], 8.14 [95% CI: 2.51, 26.39]; p < 0.001), LTI (OR, 4.96 [95% CI: 1.92, 12.83]; p < 0.001), and fasting blood glucose (FBG) (OR, 2.81 [95% CI: 1.10, 7.21]; p = 0.03) were independently associated with steatosis. The AUCs for discriminating steatosis in the model (AC with LTI) and model (AC with LTI and FBG) were 0.94 and 0.95, respectively (p = 0.15). The two-step approach, the initial visceral adiposity index (VAI) or the triglyceride × glucose (TyG) index followed by the model (AC with LTI), improved the diagnostic accuracy from 0.85 (95% CI: 0.80, 0.90) to 0.88 (95% CI: 0.84, 0.92) (p < 0.001).
CONCLUSIONS: The two-step approach, initial steatosis biomarkers followed by a multiparametric US model, might be a practical solution for discriminating steatosis in clinical practice.
引用
- Zeng J, Cai K, Zheng J, et al. A Two-Step Approach Combining Steatosis Biomarkers and Multiparametric Quantitative US Enhances Noninvasive Diagnosis of Hepatic Steatosis. Ultrasound Med Biol. 2026. PMID: 41951538. doi:10.1016/j.ultrasmedbio.2026.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。